ieumBio has been selected for PhaseⅡ of Tech Launch 2026, a global market entry and commercialization program hosted by the Korea Innovation Center Washington, D.C. (KIC DC).

Following its selection in PhaseⅠ, ieumBio successfully advanced to PhaseⅡ, where 20 startups were selected from the 40 teams participating in PhaseⅠ.

This milestone recognizes both the technological potential and global commercialization readiness of ieumBio's longevity platform.

Through the program, ieumBio will further accelerate the global development of KilliSpan™, our rapid vertebrate longevity validation platform, while expanding collaborations with pharmaceutical and biotechnology companies, research institutions, and investors in the U.S. market.

As we continue to build the global standard for vertebrate longevity validation, we look forward to creating new partnerships that will accelerate the discovery and development of interventions for healthy longevity.

We sincerely thank KIC DC for this opportunity and appreciate the continued support of our partners as we expand ieumBio's global presence.